MiRAGE: mining relationships for advanced generative evaluation in drug repositioning.

MOTIVATION: Drug repositioning, the identification of new therapeutic uses for existing drugs, is crucial for accelerating drug discovery and reducing development costs. Some methods rely on heterogeneous networks, which may not fully capture the complex relationships between drugs and diseases. However, integrating diverse biological data sources offers promise for discovering new drug-disease associations (DDAs). Previous evidence indicates that the combination of information would be conducive to the discovery of new DDAs. However, the challenge lies in effectively integrating different biological data sources to identify the most effective drugs for a certain disease based on drug-disease coupled mechanisms. RESULTS: In response to this challenge, we present MiRAGE, a novel computational method for drug repositioning. MiRAGE leverages a three-step framework, comprising negative sampling using hard negative mining, classification employing random forest models, and feature selection based on feature importance. We evaluate MiRAGE on multiple benchmark datasets, demonstrating its superiority over state-of-the-art algorithms across various metrics. Notably, MiRAGE consistently outperforms other methods in uncovering novel DDAs. Case studies focusing on Parkinson's disease and schizophrenia showcase MiRAGE's ability to identify top candidate drugs supported by previous studies. Overall, our study underscores MiRAGE's efficacy and versatility as a computational tool for drug repositioning, offering valuable insights for therapeutic discoveries and addressing unmet medical needs.

A neural network-based method for polypharmacy side effects prediction.

BACKGROUND: Polypharmacy is a type of treatment that involves the concurrent use of multiple medications. Drugs may interact when they are used simultaneously. So, understanding and mitigating polypharmacy side effects are critical for patient safety and health. Since the known polypharmacy side effects are rare and they are not detected in clinical trials, computational methods are developed to model polypharmacy side effects. RESULTS: We propose a neural network-based method for polypharmacy side effects prediction (NNPS) by using novel feature vectors based on mono side effects, and drug-protein interaction information. The proposed method is fast and efficient which allows the investigation of large numbers of polypharmacy side effects. Our novelty is defining new feature vectors for drugs and combining them with a neural network architecture to apply for the context of polypharmacy side effects prediction. We compare NNPS on a benchmark dataset to predict 964 polypharmacy side effects against 5 well-established methods and show that NNPS achieves better results than the results of all 5 methods in terms of accuracy, complexity, and running time speed. NNPS outperforms about 9.2% in Area Under the Receiver-Operating Characteristic, 12.8% in Area Under the Precision-Recall Curve, 8.6% in F-score, 10.3% in Accuracy, and 18.7% in Matthews Correlation Coefficient with 5-fold cross-validation against the best algorithm among other well-established methods (Decagon method). Also, the running time of the Decagon method which is 15 days for one fold of cross-validation is reduced to 8 h by the NNPS method. CONCLUSIONS: The performance of NNPS is benchmarked against 5 well-known methods, Decagon, Concatenated drug features, Deep Walk, DEDICOM, and RESCAL, for 964 polypharmacy side effects. We adopt the 5-fold cross-validation for 50 iterations and use the average of the results to assess the performance of the NNPS method. The evaluation of the NNPS against five well-known methods, in terms of accuracy, complexity, and running time speed shows the performance of the presented method for an essential and challenging problem in pharmacology. Datasets and code for NNPS algorithm are freely accessible at https://github.com/raziyehmasumshah/NNPS .

DPSP: a multimodal deep learning framework for polypharmacy side effects prediction.

Motivation: Because unanticipated drug-drug interactions (DDIs) can result in severe bodily harm, identifying the adverse effects of polypharmacy is one of the most important tasks in human health. Over the past few decades, computational methods for predicting the adverse effects of polypharmacy have been developed. Results: This article presents DPSP, a framework for predicting polypharmacy side effects based on the construction of novel drug features and the application of a deep neural network to predict DDIs. In the first step, a variety of drug information is evaluated, and a feature extraction method and the Jaccard similarity are used to determine similarities between two drugs. By combining these similarities, a novel feature vector is generated for each drug. In the second step, the method predicts DDIs for specific DDI events using a multimodal framework and drug feature vectors. On three benchmark datasets, the performance of DPSP is measured by comparing its results to those of several well-known methods, such as GNN-DDI, MSTE, MDF-SA-DDI, NNPS, DDIMDL, DNN, DeepDDI, KNN, LR, and RF. DPSP outperforms these classification methods based on a variety of classification metrics. The results indicate that the use of diverse drug information is effective and efficient for identifying DDI adverse effects. Availability and implementation: The source code and datasets are available at https://github.com/raziyehmasumshah/DPSP.